Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness

Cancer

Volumn 104, Issue 3, 2005, Pages 511-520

  Sengupta, Shomik ^a   Lohse, Christine M ^a   Leibovich, Bradley C ^a   Frank, Igor ^a   Thompson, R Houston ^a   Webster, W Scott ^a   Zincke, Horst ^a   Blute, Michael L ^a   Cheville, John C ^a   Kwon, Eugene D ^a,b,c  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Chromophobe; Clear cell; Coagulative tumor necrosis; Histologic subtype; Necrosis; Papillary; Renal cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHI SQUARE DISTRIBUTION; CLINICAL FEATURE; COAGULATIVE TUMOR NECROSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR NECROSIS; TUMOR VOLUME; WILCOXON SIGNED RANKS TEST;

ADENOCARCINOMA, CLEAR CELL; ADENOMA, CHROMOPHOBE; ADULT; AGED; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 22544473889     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21206     Document Type: Article

References (34)

1. Novick AC, Campbell SC. Renal tumours. In: Walsh PC, Retik AB, Vaughan EDJ, Wein AJ, editors. Campbell's urology. 8th ed. Philadelphia: W.B. Saunders, 2002:2672-2772.
2. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363:594-599.
3. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Leibovich BC, et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol. 2003;170(6 Pt 1):2225-2232.
4. Srigley JR, Hutter RV, Gelb AB, Henson DE, Kenney G, King BF, et al. Current prognostic factors-renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:994-996.
5. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663-1671.
6. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
7. Amtrup F, Hansen JB, Thybo E. Prognosis in renal carcinoma evaluated from histological criteria. Scand J Urol Nephrol. 1974;8:198-202.
8. Eskelinen M, Lipponen P, Aitto-Oja L, Hall O, Syrjanen K. The value of histoquantitative measurements in prognostic assessment of renal adenocarcinoma. Int J Cancer. 1993;55:547-554.
9. Roosen JU, Engel U, Jensen RH, Kvist E, Schou G. Renal cell carcinoma: prognostic factors. Br J Urol. 1994;74:160-164.
10. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89:604-614.
11. Leibovitch I, Lev R, Mor Y, Golomb J, Dotan ZA, Ramon J. Extensive necrosis in renal cell carcinoma specimens: potential clinical and prognostic implications. Isr Med Assoc J. 2001;3:563-565.
12. Sabo E, Boltenko A, Sova Y, Stein A, Meinhaus S, Resnick MB. Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin Cancer Res. 2001;7:533-537.
13. Ficarra V, Martignoni G, Maffei N, Brunelli M, Novara G, Zanolla L, et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer. 2005;103:68-75.
14. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649-1657.
15. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63-67.
16. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-624.
17. Ooi GC, Sagar G, Lynch D, Arkell DG, Ryan PG. Cystic renal cell carcinoma: radiological features and clinico-pathological correlation. Clin Radiol. 1996;51:791-796.
18. Cheville NF. Consequences of acute cell injury: necrosis, recovery, and hypertrophy. In: Cheville NF, editor. Ultrastructural pathology: an introduction to interpretation. Ames, IA: Iowa State University Press, 1994:81-103.
19. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131-133.
20. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:987-989.
21. Lohse CM, Blute ML, Zincke H, Weaver AL, Cheville JC. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2042 patients. Am J Clin Pathol. 2002;118:877-886.
22. Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435-441.
23. Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer. 1976;38:2469-2480.
24. Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol. 2001;166:453-456.
25. Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, Deshpande A, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281-291.
26. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48-51.
27. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol. 1997;21:621-635.
28. Brinker DA, Amin MB, de Peralta-Venturina M, Reuter V, Chan DY, Epstein JI. Extensively necrotic cystic renal cell carcinoma: a clinicopathologic study with comparison to other cystic and necrotic renal cancers. Am J Surg Pathol. 2000;24:988-995.
29. Foria V, Surendra T, Poller DN. Prognostic relevance of extensive necrosis in renal cell carcinoma. J Clin Pathol. 2005;58:39-43.
30. Hemmerlein B, Kugler A, Ozisik R, Ringert RH, Radzun HJ, Thelen P. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch. 2001;439:645-652.
31. Uzzo RG, Kolenko V, Froelich CJ, Tannenbaum C, Molto L, Novick AC, et al. The T cell death knell: immune-mediated tumor death in renal cell carcinoma. Clin Cancer Res. 2001;7:3276-3281.
32. Sharifi J, Khawli LA, Hu P, King S, Epstein AL. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybrid Hybridomics. 2001;20:305-312.
33. Li J, Hu P, Khawli LA, Epstein AL. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res. 2003;63:8384-8392.
34. Mizokami MM, Hu P, Khawli LA, Li J, Epstein AL. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics. 2003;22:197-207.